The core was originally funded in late 1992, was operation by 1993, and has synthesized to date 2,096 individual peptides for used by 15 investigators. This averages 524 peptides per year. The new core will be improved by utilization of the MacroCrown method of peptide synthesis, which is more cost-effective than our earlier methods. The Core is cost- effective, providing a purified 15-mer peptide for a total cost of $217 (including costs of personnel, supplies and maintenance of equipment), compared to having that peptide synthesized by a commercial source, which would cost $800 on average. The core will provide synthesis of peptides varying in length from 9 to 16-mers for investigators studying T cell activation, antibody specificities, or sequences within large proteins which may have biologic activity. Four methods will be offered, with MacroCrown likely to be the most frequently used. The mother methods available will be multi-pin, tea-bag and the Advanced ChemTech automatic synthesizer. The least expensive method to give yields most investigators will need will be the MacroCrown technique. Peptides will be purified by HPLC and may be sent to another UCLA facility for mass spectrometry if the investigator needs to determine exact purity. Dr. Fanny Ebling will direct this facility, and Dr. Eli Sercarz will be Associate Director. We anticipate that approximately 14 investigators currently using this facility and working with MAMDC investigators will use this core regularly, and should be able to serve several additional investigators whose programs become related to the MAMDC projects.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Jawaheer, Damini; Maranian, Paul; Park, Grace et al. (2010) Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol 37:2475-85
Kahn, Katherine L; MacLean, Catherine H; Liu, Honghu et al. (2007) The complexity of care for patients with rheumatoid arthritis: metrics for better understanding chronic disease care. Med Care 45:55-65
Kahn, K L; Maclean, C H; Wong, A L et al. (2007) Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort. Arthritis Rheum 57:707-15
Ranganath, Veena K; Yoon, Jeonglim; Khanna, Dinesh et al. (2007) Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. Ann Rheum Dis 66:1633-40
Kahn, K L; MacLean, C H; Liu, H et al. (2006) Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice. Arthritis Rheum 55:884-91
Paulus, Harold E; Oh, MyungShin; Sharp, John T et al. (2004) Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: a preliminary proposal. Arthritis Rheum 50:1083-96
Liu, Honghu; Harker, Judith O; Wong, Andrew L et al. (2004) Case finding for population-based studies of rheumatoid arthritis: comparison of patient self-reported ACR criteria-based algorithms to physician-implicit review for diagnosis of rheumatoid arthritis. Semin Arthritis Rheum 33:302-10
Riemekasten, Gabriela; Langnickel, Dirk; Enghard, Philipp et al. (2004) Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol 173:5835-42
La Cava, Antonio; Ebling, Fanny M; Hahn, Bevra H (2004) Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J Immunol 173:3542-8
Amjadi-Begvand, Sogol; Khanna, Dinesh; Park, Grace S et al. (2004) Dating the ""window of therapeutic opportunity"" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. J Rheumatol 31:1686-92

Showing the most recent 10 out of 111 publications